HK1218248A1 - 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物 - Google Patents

冻干的或可冻干形式的lkktet和/或lkktnt肽组合物 Download PDF

Info

Publication number
HK1218248A1
HK1218248A1 HK16106215.8A HK16106215A HK1218248A1 HK 1218248 A1 HK1218248 A1 HK 1218248A1 HK 16106215 A HK16106215 A HK 16106215A HK 1218248 A1 HK1218248 A1 HK 1218248A1
Authority
HK
Hong Kong
Prior art keywords
peptide
composition
amino acid
agent
peptide agent
Prior art date
Application number
HK16106215.8A
Other languages
English (en)
Chinese (zh)
Inventor
大衛．克羅克福德
大卫．克罗克福德
阿蘭．
阿兰．L.．戈尔茨坦
．戈爾茨坦
Original Assignee
雷金纳克斯生物制药公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 雷金纳克斯生物制药公司 filed Critical 雷金纳克斯生物制药公司
Publication of HK1218248A1 publication Critical patent/HK1218248A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
HK16106215.8A 2005-06-17 2016-06-01 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物 HK1218248A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69126105P 2005-06-17 2005-06-17
US60/691,261 2005-06-17
US77694706P 2006-02-28 2006-02-28
US60/776,947 2006-02-28

Publications (1)

Publication Number Publication Date
HK1218248A1 true HK1218248A1 (zh) 2017-02-10

Family

ID=37570786

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106215.8A HK1218248A1 (zh) 2005-06-17 2016-06-01 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物

Country Status (11)

Country Link
US (8) US20090131313A1 (enExample)
EP (4) EP1904080A4 (enExample)
JP (3) JP2008543878A (enExample)
KR (3) KR20080018268A (enExample)
CN (1) CN105106931A (enExample)
AU (3) AU2006261155A1 (enExample)
CA (3) CA2612405A1 (enExample)
HK (1) HK1218248A1 (enExample)
IL (4) IL187522A0 (enExample)
MX (3) MX2007015956A (enExample)
WO (3) WO2006138707A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010010177A (es) * 2008-03-17 2012-08-23 Regenerx Biopharmaceuticals Fragmentos de beta timosina mejorada.
CN101297965B (zh) * 2008-06-16 2011-01-05 浙江省中医药研究院 胸腺肽β4在制备防治支气管哮喘药物中的应用
EP2485765A2 (en) 2009-10-09 2012-08-15 Board Of Regents The University Of Texas System Photokinetic ocular drug delivery methods and apparatus
WO2012126047A1 (en) * 2011-03-18 2012-09-27 Adistem Ltd Agent and method for treating pain and reducing inflammation
KR102038948B1 (ko) 2012-03-01 2019-11-26 퍼스트스트링 리서치 인코포레이티드 알파 코넥신 c-말단 (act) 펩타이드를 포함하는 국소 겔
EP2698162A1 (en) 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
TR201902755T4 (tr) * 2013-11-07 2019-03-21 Dr August Wolff Gmbh & Co Kg Arzneimittel Depolama kararliliğina sahi̇p li̇yofi̇li̇ze tri̇pepti̇t formülasyonlari.
JP6612247B2 (ja) 2014-03-12 2019-11-27 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン 眼の感染症および疾患を処置するための組成物および方法
US10406208B2 (en) 2014-10-22 2019-09-10 G-Treebnt Co., Ltd. Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
KR20170021667A (ko) 2015-08-18 2017-02-28 주식회사 지트리비앤티 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
US9867868B2 (en) * 2015-08-18 2018-01-16 G-Treebnt Co., Ltd. Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid
KR102487614B1 (ko) 2015-10-06 2023-01-12 에이치엘비테라퓨틱스 주식회사 티모신 β4를 포함하는 안약의 제조방법
KR102488796B1 (ko) * 2016-07-18 2023-01-13 리젠트리 엘엘씨 안구 건조증 치료 방법
KR102115158B1 (ko) 2016-11-29 2020-05-26 주식회사 지트리파마슈티컬 티모신 베타 4 를 함유하는 제형
MX2019009759A (es) * 2017-02-21 2020-07-27 Tearsolutions Inc Composiciones de peptido estables.
KR102340750B1 (ko) 2017-03-03 2021-12-21 에이치엘비테라퓨틱스 주식회사 티모신 베타 4를 유효성분으로 포함하는 안정화된 외용 제제
KR101910908B1 (ko) * 2017-06-14 2018-10-24 (주)휴온스 Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물
US10342824B2 (en) 2017-07-17 2019-07-09 Dr. Marlowe's Weight Loss Institute, P.L.L.C. Supplement for treating side effects of medications which cause metabolic acidosis
US20200353052A1 (en) * 2017-11-24 2020-11-12 G-Treebnt Co., Ltd. Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient
MX2023004631A (es) 2020-10-22 2023-07-20 Xequel Bio Inc Formulaciones peptidicas y usos oftalmicos de las mismas.
CN119730839A (zh) * 2022-07-01 2025-03-28 缇尔索卢森公司 稳定的肽组合物及使用其治疗中/重度干眼相关的眼部症状的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US4906613A (en) 1985-11-05 1990-03-06 Schering Corporation Antiglaucoma compositions and methods
NZ235556A (en) 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
FR2647675B1 (fr) 1989-06-05 1994-05-20 Sanofi Utilisation d'un derive de la statine dans le traitement des affections oculaires
US5564345A (en) * 1993-05-11 1996-10-15 Park Ohio Industries Inc. Stackable table, table assembly, and tray and table combination
DK0639070T4 (da) * 1992-05-06 2010-12-13 Alcon Lab Inc Anvendelse af borat-polyolkomplekser til ophtalmiske præparater
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
WO1996003158A1 (en) 1994-07-22 1996-02-08 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
GB9806632D0 (en) 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
US20040131626A1 (en) * 2001-03-15 2004-07-08 Goldstein Allan L. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (tb4) analogues, isoforms and other derivatives
EP1591128A1 (en) * 1998-07-30 2005-11-02 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Thymosin beta 4 promotes wound repair
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
WO2002024234A2 (en) * 2000-09-20 2002-03-28 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
JP2005502672A (ja) * 2001-08-29 2005-01-27 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド サイモシンβ４、類似体、アイソフォームおよびその他の誘導体を用いて心筋障害の発生前、発生中または発生後に発生する炎症、損傷およびその他の変化を治癒または予防する方法
US20040005644A1 (en) * 2002-02-28 2004-01-08 Su Yan A. Method and composition for detection and treatment of breast cancer
AU2003278727A1 (en) * 2002-09-20 2004-04-08 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
US20060263360A1 (en) 2003-03-31 2006-11-23 Regenerx Biopharmaceuticals, Inc. Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives
WO2004099768A1 (en) * 2003-05-05 2004-11-18 Regenerx Biopharmaceuticals, Inc. Method for detecting development of a physiological disorder in a subject
KR102632066B1 (ko) 2015-07-30 2024-02-02 가부시키가이샤 한도오따이 에네루기 켄큐쇼 발광 장치의 제작 방법, 발광 장치, 모듈, 및 전자 기기

Also Published As

Publication number Publication date
EP1904080A4 (en) 2011-02-16
CA2612522A1 (en) 2006-12-28
WO2006138708B1 (en) 2007-04-05
JP2008543879A (ja) 2008-12-04
IL218504A (en) 2013-10-31
KR20080033939A (ko) 2008-04-17
US20120071411A1 (en) 2012-03-22
WO2006138709A3 (en) 2007-07-05
US9821030B2 (en) 2017-11-21
US8383576B2 (en) 2013-02-26
KR20080021782A (ko) 2008-03-07
MX2007015956A (es) 2008-03-06
JP2008543877A (ja) 2008-12-04
IL187781A (en) 2012-04-30
CA2612405A1 (en) 2006-12-28
MX2007015957A (es) 2008-03-06
IL187781A0 (en) 2008-08-07
WO2006138709A2 (en) 2006-12-28
IL187522A0 (en) 2008-03-20
IL187617A0 (en) 2008-03-20
US20160287673A1 (en) 2016-10-06
US20090131313A1 (en) 2009-05-21
IL218504A0 (en) 2012-04-30
KR20080018268A (ko) 2008-02-27
EP1906986A1 (en) 2008-04-09
CA2612410A1 (en) 2006-12-28
AU2006261157A1 (en) 2006-12-28
AU2006261156A1 (en) 2006-12-28
EP1904080A1 (en) 2008-04-02
EP1896050A2 (en) 2008-03-12
US20090118196A1 (en) 2009-05-07
US20080214456A1 (en) 2008-09-04
US20170128540A1 (en) 2017-05-11
US9585941B2 (en) 2017-03-07
AU2006261155A1 (en) 2006-12-28
JP2008543878A (ja) 2008-12-04
US20180028619A1 (en) 2018-02-01
AU2006261156B2 (en) 2012-05-31
US20160193301A1 (en) 2016-07-07
MX2007015958A (es) 2008-04-17
EP3326647A1 (en) 2018-05-30
CN105106931A (zh) 2015-12-02
WO2006138707A1 (en) 2006-12-28
WO2006138708A1 (en) 2006-12-28
EP1896050A4 (en) 2010-01-27
US10004785B2 (en) 2018-06-26
EP1906986A4 (en) 2011-02-23

Similar Documents

Publication Publication Date Title
US10004785B2 (en) LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized
ZA200503975B (en) Use of rimexolone in the treatment of dry eye
WO2008108927A2 (en) Methods and compositions for stabilizing polypeptides
JP2025513090A (ja) 眼疾患の治療のためのミコフェノール酸及び／又はベタメタゾンの医薬組成物
JP2023530188A (ja) 高分子量ヒアルロン酸の眼科用薬物輸送ビヒクルとしての使用
CN101198346A (zh) Lkktet和/或lkktnt肽组合物及方法
HK1256177A1 (en) Lkktet and/or lkktnt peptide compositions which are lyophilized or in a form capable of being lyophilized
US20230158045A1 (en) Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders
CN119730839A (zh) 稳定的肽组合物及使用其治疗中/重度干眼相关的眼部症状的方法